Wave of AI and data science tools set to transform clinical trials
The clinical trial sector is experiencing a rapid influx of artificial intelligence (AI) and data science tools, as companies seek…
Analysis
EU’s Joint Clinical Assessment system still finding its footing
The slow march of clinical biomarkers to become surrogate endpoints
Lifyorli (relacorilant) for the Treatment of Platinum-Resistant Ovarian Cancer, US
GEMTESA for the Treatment of Overactive Bladder, US
Biomarker-led trials to guide the future of precision psychiatry
Filspari (sparsentan) for the Reduction of Proteinuria in IgA Nephropathy, US
Preparation is key to understanding global trade compliance for trials
